Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.098
Buy
RSI(14)
68.181
Neutral
STOCH(KDJ)(9,3,3)
82.812
Neutral
ATR(14)
0.190
High Vlolatility
CCI(14)
192.336
Buy
Williams %R
12.941
Overbought
TRIX(12,20)
0.140
Sell
StochRSI(14)
100.000
Buy
Takeda Pharmaceutical Co Ltd
TAK14.915USD
+0.085+0.57%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
47.12BMarket Cap
209.33P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Takeda Pharmaceutical Co Ltd
Currency: USD Updated: 2025-12-19Key Insights
Takeda Pharmaceutical Co Ltd's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 53/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.10.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Takeda Pharmaceutical Co Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
18.100
Target Price
+27.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Takeda Pharmaceutical Co Ltd Highlights
StrengthsRisks
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 287.84%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 287.84%.
Overvalued
The company’s latest PE is 209.12, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 78.67M shares, decreasing 2.19% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 80.78K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Takeda Pharmaceutical Co Ltd is 7.62, ranking 106/158 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 7.22B, representing a year-over-year decrease of 6.66%, while its net profit experienced a year-over-year decrease of 112.65%.
Score
Financials
6.33
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
2.69
Operational Efficiency
10.00
Growth Potential
9.52
Shareholder Returns
9.54
Takeda Pharmaceutical Co Ltd's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Takeda Pharmaceutical Co Ltd is 5.68, ranking 144/158 in the Pharmaceuticals industry. Its current P/E ratio is 209.12, which is 0.00% below the recent high of 209.12 and 95.16% above the recent low of 10.12.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 53/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Takeda Pharmaceutical Co Ltd is 8.67, ranking 13/158 in the Pharmaceuticals industry. The average price target for Takeda Pharmaceutical Co Ltd is 18.00, with a high of 19.30 and a low of 17.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
18.100
Target Price
+27.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Takeda Pharmaceutical Co Ltd
TAK
3
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Takeda Pharmaceutical Co Ltd is 9.13, ranking 33/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 15.24 and the support level at 14.32, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
14.668
Buy
MA10
14.491
Buy
MA20
14.419
Buy
MA50
14.102
Buy
MA100
14.470
Buy
MA200
14.644
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Takeda Pharmaceutical Co Ltd is 3.00, ranking 92/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 2.49%, representing a quarter-over-quarter increase of 8.07%. The largest institutional shareholder is Brandes Investmen, holding a total of 3.93M shares, representing 0.12% of shares outstanding, with 10.96% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Capital Research Global Investors
Parametric Portfolio Associates LLC
UBS Financial Services, Inc.
Fidelity Management & Research Company LLC
Goldman Sachs Asset Management, L.P.
Aperio Group, LLC
Arrowstreet Capital, Limited Partnership
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Takeda Pharmaceutical Co Ltd is 9.46, ranking 9/158 in the Pharmaceuticals industry. The company's beta value is 0.06. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.06
VaR
+1.97%
240-Day Maximum Drawdown
+14.76%
240-Day Volatility
+21.18%
Return
Best Daily Return
60 days
+2.49%
120 days
+3.21%
5 years
+4.69%
Worst Daily Return
60 days
-3.92%
120 days
-5.03%
5 years
-11.01%
Sharpe Ratio
60 days
+0.00
120 days
-0.30
5 years
-0.14
Risk Assessment
Maximum Drawdown
240 days
+14.76%
3 years
+26.36%
5 years
+37.59%
Return-to-Drawdown Ratio
240 days
+0.82
3 years
-0.08
5 years
-0.10
Skewness
240 days
-0.77
3 years
-0.85
5 years
-0.98
Volatility
Realised Volatility
240 days
+21.18%
5 years
+18.72%
Standardised True Range
240 days
+1.51%
5 years
+1.43%
Downside Risk-Adjusted Return
120 days
-36.74%
240 days
-36.74%
Maximum Daily Upside Volatility
60 days
+15.47%
Maximum Daily Downside Volatility
60 days
+16.78%
Liquidity
Average Turnover Rate
60 days
+0.22%
120 days
+0.18%
5 years
--
Turnover Deviation
20 days
+61.14%
60 days
+68.03%
120 days
+35.12%
Peer Comparison
Pharmaceuticals
Takeda Pharmaceutical Co Ltd
TAK
7.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Takeda Pharmaceutical Co Ltd?
The TradingKey Stock Score provides a comprehensive assessment of Takeda Pharmaceutical Co Ltd based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Takeda Pharmaceutical Co Ltd’s performance and outlook.
How do we generate the financial health score of Takeda Pharmaceutical Co Ltd?
To generate the financial health score of Takeda Pharmaceutical Co Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Takeda Pharmaceutical Co Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Takeda Pharmaceutical Co Ltd.
How do we generate the company valuation score of Takeda Pharmaceutical Co Ltd?
To generate the company valuation score of Takeda Pharmaceutical Co Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Takeda Pharmaceutical Co Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Takeda Pharmaceutical Co Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Takeda Pharmaceutical Co Ltd.
How do we generate the earnings forecast score of Takeda Pharmaceutical Co Ltd?
To calculate the earnings forecast score of Takeda Pharmaceutical Co Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Takeda Pharmaceutical Co Ltd’s future.
How do we generate the price momentum score of Takeda Pharmaceutical Co Ltd?
When generating the price momentum score for Takeda Pharmaceutical Co Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Takeda Pharmaceutical Co Ltd’s prices. A higher score indicates a more stable short-term price trend for Takeda Pharmaceutical Co Ltd.
How do we generate the institutional confidence score of Takeda Pharmaceutical Co Ltd?
To generate the institutional confidence score of Takeda Pharmaceutical Co Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Takeda Pharmaceutical Co Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Takeda Pharmaceutical Co Ltd.
How do we generate the risk management score of Takeda Pharmaceutical Co Ltd?
To assess the risk management score of Takeda Pharmaceutical Co Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Takeda Pharmaceutical Co Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Takeda Pharmaceutical Co Ltd.
